Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven

About this update from Cosmos Health Inc.

[{"type":"image","alt":"Cosmos Health Inc.","displaySize":"","headline":null,"caption":"Cosmos Health Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/340010e4b2fe348130647e37170a6c2a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zU4V54zW1TjV8qFkho7Qmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/340010e4b2fe348130647e37170a6c2a","width":300,"height":157}},"lazy":false},{"type":"text","content":"CHICAGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the first quarter ended March 31, 2025.","length":443,"tagName":"p"},{"type":"text","content":"First Quarter 2025 Financial Highlights","length":39,"tagName":"p"},{"type":"text","content":"Income Statement Cosmos Health delivered solid results in Q1 2025, highlighted by a significant increase in gross profit and positive performance on both an Adjusted EBITDA and Adjusted Net Income basis, reflecting a meaningful turnaround in bottom-line performance.","length":268,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue for Q1 2025 was $13.71 million, a decrease of 5.98% from $14.58 million in Q1 2024, primarily reflecting the Company’s strategic shift toward higher-margin focus areas and a disciplined reduction of promotional-dependent activities.","length":240,"tagName":"p"}]},{"val":[{"type":"text","content":"Gross profit increased by 53.70% to $2.05 million, up from $1.33 million in the prior-year period, driven by an improved product mix and operational leverage. Segment contributions were as follows:","length":197,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Wholesale logistics distribution: $1.18 million","length":47,"tagName":"p"}]},{"val":[{"type":"text","content":"Owned nutraceuticals/pharmaceuticals and manufacturing: $0.87 million","length":69,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":116,"olType":false}]},{"val":[{"type":"text","c...

More updates from Cosmos Health Inc.